plerixafor has been researched along with Chronic Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, S; Auer, N; Chakraborty, A; Condon, D; de Jesus Perez, VA; Liu, Y; Nathan, A; Nicolls, MR; Shamshou, EA; Sweatt, AJ; Tian, W; Wu, JC; Yu, J; Yuan, K; Zamanian, RT; Zhang, S; Zhang, Y | 1 |
| Bachelerie, F; Balabanian, K; Biajoux, V; Bonnet, D; Bouchet-Delbos, L; Brotin, E; Emilie, D; Fenneteau, O; Fiette, L; Lainey, E | 1 |
2 other study(ies) available for plerixafor and Chronic Disease
| Article | Year |
|---|---|
Mural Cell SDF1 Signaling Is Associated with the Pathogenesis of Pulmonary Arterial Hypertension.
Topics: Animals; Antigens; Benzylamines; Cell Division; Cell Lineage; Chemokine CXCL12; Chronic Disease; Cyclams; DNA Nucleotidylexotransferase; Gene Expression Regulation; Gene Knockdown Techniques; Heterocyclic Compounds; Hypertension, Pulmonary; Hypoxia; Mice; Mice, Transgenic; Models, Biological; Myocytes, Smooth Muscle; Pericytes; Proteoglycans; Receptors, CXCR4; Recombinant Proteins; RNA, Messenger; Signal Transduction; Vasoconstriction | 2020 |
Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice.
Topics: Animals; B-Lymphocytes; Benzylamines; Bone Marrow; Cell Compartmentation; Chemokine CXCL12; Chemotaxis; Chronic Disease; Cyclams; Desensitization, Immunologic; Heterocyclic Compounds; Homeostasis; Humans; Lymph Nodes; Lymphocyte Count; Lymphocytes; Mice; Mutation; Neutropenia; Receptors, CXCR4; Signal Transduction; T-Lymphocytes | 2012 |